Seattle Genetics: More Adcetris data at ASH
Seattle Genetics Inc. (NASDAQ:SGEN) was off $2.98 to $38.30 on Monday after reporting Adcetris brentuximab vedotin met the primary endpoint of improving progression-free survival (PFS) vs. placebo (HR=0.57, p=0.001) in the Phase III AETHERA trial to treat patients with Hodgkin's lymphoma (HL) who are at risk of progression following an autologous stem cell transplant (ASCT). The company said the data equate to a 75% gain in PFS for the treated arm.
No statistically significant difference was seen between the two treatment arms in an interim analysis of overall survival (OS). On a conference call, Seattle Genetics deferred several analyst questions about the OS results, noting that median OS has not been reached and the next readout would be expected in 2016. The company said the next AETHERA presentation, at the American Society of Hematology (ASH) meeting in December, would provide details on the PFS data and safety results. ...